Transcatheter Aortic Valve Replacement Market Size to Hit USD 12.22 Billion by 2034

The global transcatheter aortic valve replacement market size accounted for USD 6.15 billion in 2024 and is predicted to touch around USD 12.22 billion by 2034, growing at a CAGR of 7.1% from 2025 to 2034.

Highlights of the Transcatheter Aortic Valve Replacement (TAVR) Market

• By implantation procedure, the transfemoral segment holds a dominant presence in the market in 2024.
• By implantation procedure, the transapical segment is anticipated to grow at the fastest rate in the market during the forecast period.
• By material, the nitinol segment holds a dominant presence in the transcatheter aortic valve replacement (TAVR) market in 2024.
• By material, the cobalt-chromium segment is anticipated to grow at the fastest rate in the market during the forecast period.
• By mechanism, the balloon-expanding segment holds a dominant presence in the transcatheter aortic valve replacement (TAVR) market in 2024.
• By mechanism, the self-expanding valve segment is anticipated to grow at the fastest rate in the market during the forecast period.
• By end-use, the hospitals segment holds a dominant presence in the transcatheter aortic valve replacement (TAVR) market in 2024.
• By end-use, the ambulatory surgical centers segment is anticipated to grow at the fastest rate in the market during the forecast period.
• By region, North America dominated the global transcatheter aortic valve replacement (TAVR) market in 2024.
• By region, Asia Pacific is anticipated to grow at the fastest rate in the market during the forecast period.

Industry Valuation and Growth Rate Projection

Transcatheter aortic valve implantation is referred to as a minimally invasive process in which a narrowed aortic valve is replaced, and it is not open-heart surgery. It is used for the treatment of aortic stenosis. TAVR includes the implantation of transcatheter aortic valves to restore the blood circulation capability of the aortic valve. The demand for transcatheter aortic valve implantation is on the rise because of the increase in the incidence of aortic stenosis.

Transcatheter Aortic Valve Replacement (TAVR) Market: Stats and Figures

• In March 2025, JenaValve Technology, Inc., offered results from an expansion cohort of 500 individuals in the ALIGN-AR Pivotal Trial for the Trilogy THV System in high-risk patients with symptomatic, severe aortic regurgitation (AR).

Industry Leader Announcements

• Sascha Daeuber, Radiology Platform Leader at Bracco Imaging

"We are proud to extend our successful partnership with Subtle Medical into the European market," said Sascha Daeuber, Radiology Platform Leader at Bracco Imaging. "From the beginning, Subtle has proven to be an agile and visionary partner, our joint announcement of FDA clearance last year underscored that strength. With the CE Mark for AiMIFY, we're taking the next step in our shared mission to deliver innovative, AI-powered solutions that enhance diagnostic precision and support radiologists and patients worldwide."

• Josef Bogenschütz, CEO of CoreMedic

“We are thrilled to announce the expansion of our investor syndicate with the addition of MIG Capital, which has deep domain investment experience in building companies from seed to expansion across market sectors. We welcome Matthias Guth to our esteemed Board. This is a significant milestone in the further development of our company and will support us in achieving our goals,” said Josef Bogenschütz, CEO of CoreMedic.

How AI Has Benefitted the Transcatheter Aortic Valve Replacement (TAVR) Market

Transcatheter aortic valve replacement (TAVR) has been a viable option for surgical aortic valve replacement, as collecting clinical evidence has shown its safety and efficacy. The field of cardiology is witnessing remarkable advancements boosted by the incorporation of artificial intelligence techniques in numerous domains. Artificial intelligence, fueled by developed computational abilities and efficient data processing, has opened new avenues for enhancing care and decreasing costs in medicine. Increased availability of large sets of information and developing computing power has contributed to a surge in supervised machine learning approaches with a broader range of potential applications, including the determination of prospects therapeutic targets and drug development.

Recent Developments in the Transcatheter Aortic Valve Replacement (TAVR) Market

In January 2025, Abbott started Navitor Vision, the next-generation transcatheter aortic valve implantation/replacement (TAVI/TAVR) system in India. Programmed to treat symptomatic severe aortic stenosis in patients at high or extreme surgical risk, Navitor Vision introduces improved features to enhance precision and outcomes during minimally invasive procedures.

Geographical Insights

The transcatheter aortic valve replacement (TAVR) market is experiencing significant growth, with North America maintaining its position as the dominant region while Europe emerges as the rapidly growing market. The Asia Pacific region is projected to be the fastest-growing in the transcatheter aortic valve replacement (TAVR) market during the forecast period.

North America

North America dominated the global transcatheter aortic valve replacement (TAVR) market in 2024. The region has a well-known healthcare system with the essential infrastructure for TAVR procedures. High levels of healthcare expenditure led to the requirement for TAVR procedures. This dominance is attributed to factors such as developed healthcare infrastructure, high knowledge levels, and strong healthcare spending.

Europe

Europe is experiencing rapid growth in the transcatheter aortic valve replacement (TAVR) market during the forecast period. The increasing incidence of aortic stenosis in older populations is a major factor leading to the growth in TAVR procedures. Continuous developments in TAVR technology and valve design have enhanced outcomes and expanded the patient pool eligible for the procedure. There's a move towards accelerating TAVR to intermediate-risk patients derived from positive clinical trial results.

Asia Pacific

Asia Pacific is projected to be the fastest-growing transcatheter aortic valve replacement (TAVR) market during the forecast period. The increasing incidence of aortic stenosis, which is associated with aging, is a key contributor to driving the requirement for TAVR procedures. Some countries in the Asia Pacific are growing attractive destinations for medical tourism, thus boosting the requirement for TAVR procedures. Growing knowledge among healthcare professionals and physicians about the advantages of TAVR is also leading to its increased adoption.

Competitive Landscape

The TAVR market is highly competitive, and these firms focus on continuous innovation, mainly in delivery systems and valve design, to maintain their leading positions. The market is characterized by strategic partnerships, ongoing research and development, and a focus on expanding access to numerous patient populations.

• Company Name: Medtronic plc
• Year of Incorporation: 2015
• Headquarters: Dublin, Ireland

Medtronic plc (Medtronic) is a medical technology firm that develops, designs, manufactures, and markets medical devices and solutions. The firm's major activities include design, manufacturing, research, and sales of biomedical engineering goods. Medtronic also offers biologic solutions for the dental and orthopedic markets.

• Company Name: Abbott Laboratories, Inc.
• Year of Incorporation: 1900
• Headquarters: Chicago, Illinois, United States

Abbott Laboratories (Abbott) is a medical apparatus and healthcare firm that develops, manufactures, discovers, and sells products. It mainly provides gastroenterology products, cardiovascular and metabolic products, women’s health products, pain and central nervous system products, biosimilar products, respiratory drugs and vaccines, core laboratory and transfusion medicine systems, and fast diagnostics lateral flow testing products.

• Company Name: Boston Scientific Corporation
• Year of Incorporation: 1979
• Headquarters: Marlborough, Massachusetts, United States

Boston Scientific Corp (Boston Scientific) is a medical technology firm that develops, produces, and commercializes apparatus for a range of interventional medical specialties. Boston Scientific serves clinics, hospitals, outpatient facilities, and medical offices all over the world.

Transcatheter Aortic Valve Replacement Market Share, By Procedure, 2024 (%)

• Transfemoral Implantation – Holds 76% as the least invasive and most widely adopted access route, dominating due to faster recovery and reduced surgical risk.
• Transapical Implantation – Represents 2%, used only when transfemoral access is not feasible, not dominating due to high invasiveness and declining clinical preference.
• Transaortic Implantation – Accounts for 22%, serving complex anatomical cases, gaining selective use but not dominating because it is more invasive and risk-intensive than transfemoral.

Transcatheter Aortic Valve Replacement Market Share, By Indication, 2024 (%)

• Aortic Stenosis (AS) – Holds 75%, forming the primary clinical application, dominating due to high prevalence among aging populations.
• Aortic Regurgitation (AR) – Represents 16%, supporting specialized valve replacement needs, not dominating due to narrower patient eligibility.
• Mixed AS/AR – Accounts for 10%, targeting combined valvular dysfunction, not dominating due to smaller diagnosis volume.

Transcatheter Aortic Valve Replacement Market Share, By Mechanism, 2024 (%)

• Balloon-expanding Valve – Holds 42%, delivering precise positioning and controlled deployment, maintaining strong share but not dominating due to higher complication risk in certain anatomies.
• Self-expanding Valve – Leads with 58%, engineered for flexible placement and broader anatomical suitability, dominating due to superior performance in complex cases.

Transcatheter Aortic Valve Replacement Market Share, By End Users, 2024 (%)

• Hospitals – Captures 46%, performing most TAVI procedures with full surgical infrastructure, sharing dominance due to high patient volume and specialist capability.
• Ambulatory Surgical Centres – Also holds 46%, rapidly growing as TAVI shifts toward minimally invasive outpatient procedures, gaining momentum through reduced costs and shorter stays.
• Others – Accounts for 8%, including specialty cardiac centers, not dominating due to low procedural volume.